These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 19709328)

  • 1. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
    Sweileh WM
    Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gentamicin and amikacin nephrotoxicity: comparative study in patients with initially normal renal function].
    Ballesteros J; Northland R; Wolff M
    Rev Med Chil; 1989 Jan; 117(1):10-7. PubMed ID: 2641618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in aminoglycoside induced nephrotoxicity: a prospective, hospital-based study.
    Sweileh WM
    Curr Clin Pharmacol; 2009 Sep; 4(3):229-32. PubMed ID: 19500072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proximal tubule damage in patients treated with gentamicin or amikacin.
    Wiland P; Szechciński J
    Pol J Pharmacol; 2003; 55(4):631-7. PubMed ID: 14581723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity induced by gentamicin and amikacin.
    Smith CR; Maxwell RR; Edwards CQ; Rogers JF; Lietman PS
    Johns Hopkins Med J; 1978 Mar; 142(3):85-90. PubMed ID: 342789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
    Kiel PJ; Lo M; Stockwell D; Patel GP
    Am J Ther; 2008; 15(2):131-6. PubMed ID: 18356633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the safety of isepamicin in adults.
    Blum D
    J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
    Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
    Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
    Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
    Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R
    J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum albumin and the increased risk of amikacin nephrotoxicity.
    Contreras AM; Ramírez M; Cueva L; Alvarez S; de Loza R; Gamba G
    Rev Invest Clin; 1994; 46(1):37-43. PubMed ID: 8079062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
    Covi M; Velluti G
    J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once daily isepamicin treatment in complicated urinary tract infections.
    Lee SS; Liu YC; Wann SR; Lin WR; Tsai TH; Lin HH; Chen YS; Yen MY
    J Microbiol Immunol Infect; 1999 Jun; 32(2):105-10. PubMed ID: 11561574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
    Colardyn F
    J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dosing aminoglycosides once a day].
    Blaser J
    Schweiz Med Wochenschr Suppl; 1996; 76():39S-48S. PubMed ID: 8677418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of single daily dose gentamicin in stem cell transplantation.
    Warkentin D; Ippoliti C; Bruton J; Van Besien K; Champlin R
    Bone Marrow Transplant; 1999 Jul; 24(1):57-61. PubMed ID: 10435736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis.
    Bailey RR; Begg EJ; Smith AH; Robson RA; Lynn KL; Chambers ST; Barclay ML; Hornibrook J
    Clin Nephrol; 1996 Sep; 46(3):183-6. PubMed ID: 8879853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.